Who are Tacrolimus and Everolimus's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tacrolimus-and-everolimus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tacrolimus and Everolimus — Competitive Intelligence Brief

Tacrolimus and Everolimus (Tacrolimus and Everolimus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant (calcineurin inhibitor and mTOR inhibitor combination). Area: Immunology / Transplantation.

marketed Immunosuppressant (calcineurin inhibitor and mTOR inhibitor combination) Calcineurin (tacrolimus) and mTOR (everolimus) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Tacrolimus and Everolimus (Tacrolimus and Everolimus) — Chang Gung Memorial Hospital. Tacrolimus and everolimus are immunosuppressive agents that inhibit mTOR and calcineurin pathways to prevent T-cell activation and proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tacrolimus and Everolimus TARGET	Tacrolimus and Everolimus	Chang Gung Memorial Hospital	marketed	Immunosuppressant (calcineurin inhibitor and mTOR inhibitor combination)	Calcineurin (tacrolimus) and mTOR (everolimus)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant (calcineurin inhibitor and mTOR inhibitor combination) class)

Chang Gung Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tacrolimus and Everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-and-everolimus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab